NCT00189930View on ClinicalTrials.gov

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

December 31, 2006

Conditions
HIV Infection
Interventions
BIOLOGICAL

MVA-nef

3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm

BIOLOGICAL

IMVAMUNE

3 immunizations: 1E8\_TCID50 IMVAMUNE

Trial Locations (5)

80335

Doctor's Practice, Munich

80801

Doctor's Practice, Munich

90641

Doctor's Practice, Nuremberg

90762

Doctor's Practice, Fürth

91054

University of Erlangen, Erlangen

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Bavarian Nordic

INDUSTRY